Loading
The PD-1 antibody nivolumab produced responses in about seven in ten patients whose Hodgkin lymphoma had returned after a stem cell transplant, with responses lasting well over a year, confirming the exquisite sensitivity of this lymphoma to checkpoint blockade.
Multicohort single-arm phase 2 study of 243 patients with classical Hodgkin lymphoma relapsed or refractory after autologous stem cell transplantation, treated with nivolumab; cohorts were brentuximab-naive, brentuximab after transplant, and brentuximab before and/or after transplant.
With extended follow-up the objective response rate was 69 percent, median duration of response 16.6 months and median progression-free survival 14.7 months; responses were independent of PD-L1 expression level, and the safety profile matched other nivolumab studies. The data underpinned regulatory approval of nivolumab in this setting.
Nivolumab, like pembrolizumab, is a standard for relapsed Hodgkin lymphoma after transplant, and the activity seen here led to its testing in first-line therapy (S1826).
Shares CheckMate 205, Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage.
Shares CheckMate 205, Nivolumab.
Shares Relapsed and refractory classical Hodgkin lymphoma, Journal of Clinical Oncology.
Shares Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage, Nivolumab.
Shares Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage, Relapsed and refractory classical Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Nivolumab.